Emergence of Canonical and Noncanonical Genomic Variants following <i>In Vitro</i> Exposure of Clinical Mycobacterium tuberculosis Strains to Bedaquiline or Clofazimine-Reference-Cited by-同舟云学术

Emergence of Canonical and Noncanonical Genomic Variants following In Vitro Exposure of Clinical Mycobacterium tuberculosis Strains to Bedaquiline or Clofazimine

Published:2023-04-18 Issue:4 Volume:67 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Ismail N.¹²^ORCID,Dippenaar A.³^ORCID,Warren R. M.¹,Peters R. P. H.²⁴,Omar S. V.⁴⁵

Affiliation:

1. SAMRC Centre for Tuberculosis Research/DSI-NRF Centre of Excellence for Biomedical Tuberculosis Research Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa

2. Department of Medical Microbiology, Faculty of Health Sciences, University of Pretoria, Prinshof, Gauteng, South Africa

3. Global Health Institute, Department of Family Medicine and Population Health, Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium

4. Department of Medical Microbiology, School CAPHRI (Care and Public Health Research Institute), Maastricht University, Maastricht, The Netherlands

5. National Institute for Communicable Diseases/National Health Laboratory Service, Centre for Tuberculosis, National TB Reference Laboratory & WHO Supranational TB Reference Laboratory, Johannesburg, Gauteng, South Africa

Abstract

In Mycobacterium tuberculosis , bedaquiline and clofazimine resistance occurs primarily through Rv0678 variants, a gene encoding a repressor protein that regulates mmpS5 / mmpL5 efflux pump gene expression. Despite the shared effect of both drugs on efflux, little else is known about other pathways affected.

Funder

Research Foundation Flanders

National Research Foundation

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/aac.01368-22

Reference45 articles.

1. WHO. 2019. WHO consolidated guidelines on drug-resistant tuberculosis treatment. https://apps.who.int/iris/rest/bitstreams/1211676/retrieve. Accessed 9 January 2023.

2. Bedaquiline and clofazimine: successes and challenges

3. Identification of novel mutations associated with clofazimine resistance inMycobacterium tuberculosis: Table 1.

4. Clofazimine Exposure In Vitro Selects Efflux Pump Mutants and Bedaquiline Resistance

5. Acquired Resistance of Mycobacterium tuberculosis to Bedaquiline

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Commensal antimicrobial resistance mediates microbiome resilience to antibiotic disruption;Science Translational Medicine;2024-01-17

2. Pretomanid resistance: An update on emergence, mechanisms and relevance for clinical practice;International Journal of Antimicrobial Agents;2023-10